Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals orders, deals and press releases
17 filed, newest first.
Aug 2021
Sep 2020
Mar 2017
Jul 2016
Jun 2016
Nov 2013
20 Nov · Business
After successful of launch of RARICAP in oral dosage forms in Domestic Market. The Company has launched RARICAP in injection form ....
Jul 2013
25 Jul · Business
Company has received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers’ ....
May 2013
Mar 2011
22 Mar · Business
On March 22, 2011, the Company has signed an agreement with NR Jet, an affiliate of Johnson & Johnson Limited, for acquisition of the TradeMark ....
Jan 2011
25 Jan · Business
With reference to the earlier announcement dated January 25, 2011 regarding Udyog Rattan Award and Excellence Award from the Institute of Economics Studies Delhi, Bafna Pharmaceuticals ....25 Jan · Business
Company has received Udyog Rattan Award and Excellence Award from Mr. Korn Dabbaransi, former Deputy Prime Minister of Thailand held ....18 Jan · Business
Company has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of ....
Apr 2010
Jan 2010
18 Jan · Business
Company have been awarded the Gold Quality Excellence Award 2009 (Turnover between 25 Crores to 75 Crores) from Indian Drug Manufacturers ....